These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1008913)

  • 21. Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
    Kaffarnik H; Schneider J; Schubotz R; Zöfel P; Hausmann L; Goebel KM
    Artery; 1980; 8(6):537-46. PubMed ID: 6114725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The common hyperlipoproteinemias: an understanding of disease mechanisms and their control.
    Fisher WR; Truitt DH
    Ann Intern Med; 1976 Oct; 85(4):497-508. PubMed ID: 184730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A physician's guide to hyperlipidemia.
    Fredrickson DS
    Mod Concepts Cardiovasc Dis; 1972 Jul; 41(7):31-6. PubMed ID: 4343098
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical study with a new antihyperlipemic combination].
    Pistautz H
    Arzneimittelforschung; 1977; 27(1):152-6. PubMed ID: 576816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition.
    Föger B; Tröbinger G; Ritsch A; Lechleitner M; Hopferwieser T; Menzel HJ; Utermann G; Pfeiffer KP; Patsch JR
    Atherosclerosis; 1995 Oct; 117(2):253-61. PubMed ID: 8801871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of niceritrol (pentaerythritoltetranicotinate) and clofibrate upon hyperlipemia and atherosclerosis induced in rabbits by cholesterol-free semisynthetic diets.
    Brattsand R
    Atherosclerosis; 1974; 20(3):453-67. PubMed ID: 4373017
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of etofibrate, clofibrate and nicotinic acid on the cyclic AMP-protein kinase system in rats.
    Catalán RE; Aragones MD; Martinez AM; Armijo M; Priego JG
    Gen Pharmacol; 1979; 10(6):455-8. PubMed ID: 230120
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of hyperlipidemia.
    Levy RI; Morganroth J; Rifkind BM
    N Engl J Med; 1974 Jun; 290(23):1295-301. PubMed ID: 4363888
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacological enhancement and short-term stimulation of blood fibrinolytic activity.
    Laursen B; Gormsen J
    Scand J Haematol; 1969; 6(6):402-8. PubMed ID: 5374117
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clofibrate treatment of diabetics with hyperproteinemias (author's transl)].
    Jung W; Kremer GJ; Müller D
    MMW Munch Med Wochenschr; 1975 Oct; 117(44):1783-6. PubMed ID: 171564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma protein concentrations in hypertriglyceridaemic subjects. Effect of clofibrate and comparison with normal subjects.
    Ballantyne FC; Morrison BA; Ballantyne D; Dryburgh FJ; Epenetos AA
    Clin Chim Acta; 1978 Jul; 87(1):43-7. PubMed ID: 668144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 34. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
    Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
    Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
    Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hyperlipoproteinemia type II with etofibrate.
    Gustafson A
    Int J Clin Pharmacol Biopharm; 1979 Dec; 17(12):498-502. PubMed ID: 528096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
    Gaertner U; Johannes KJ
    MMW Munch Med Wochenschr; 1976 Sep; 118(36):1127-30. PubMed ID: 184377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of clofibrate on blood viscosity in primary hyperlipoproteinemia.
    Arntz HR; Leonhardt H; Dreykluft HR
    Klin Wochenschr; 1979 Jan; 57(1):43-7. PubMed ID: 215822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma carnitine and lipid-lowering drugs.
    Nestruck AC; Pande SV; Davignon J
    Atherosclerosis; 1985 Jun; 55(3):353-6. PubMed ID: 4015753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.